ALNYLAM PHARMACEUTICALS, INC. (18)
Browse by Contract Category
Contracts
-
Letter Agreement between the Registrant and Barry E. Greene dated August 26, 2020
(Filed With SEC on November 5, 2020)
-
First Amendment to Lease entered into between the Registrant and RREEF America REIT II CORP. PPP dated September 30, 2020
(Filed With SEC on November 5, 2020)
-
Purchase and Sale Agreement dated April 10, 2020 between BX Bodyguard Royalties L.P. and the Registrant
(Filed With SEC on August 6, 2020)
-
Amended and Restated Annual Incentive Program
(Filed With SEC on February 13, 2020)
-
Amendment to License and Collaboration Agreement, dated as of November 22, 2019 between the Registrant and The Medicines Company
(Filed With SEC on February 13, 2020)
-
Amended and Restated ALN-AT3 Global License Terms entered into as of April 8, 2019 by and between the Registrant and Genzyme Corporation
(Filed With SEC on August 6, 2019)
-
First Amendment to
(Filed With SEC on November 5, 2020)
-
Co-Development Agreement between the Registrant and BXLS
(Filed With SEC on November 5, 2020)
-
Patent Cross-License Agreement dated April 3, 2020 between Dicerna Pharmaceuticals, Inc. and the Registrant
(Filed With SEC on August 6, 2020)
-
Description of Capital Stock
(Filed With SEC on February 13, 2020)
-
Amended and Restated Investor Agreement dated as of April 8, 2019 by and between the Registrant and Genzyme Corporation
(Filed With SEC on August 6, 2019)
-
Investor Agreement dated as of April 8, 2019 by and between the Registrant and Regeneron Pharmaceuticals, Inc
(Filed With SEC on August 6, 2019)
-
Stock Purchase Agreement dated as of April 8, 2019 by and between the Registrant and Regeneron Pharmaceuticals, Inc
(Filed With SEC on August 6, 2019)
-
Amendment No. 3 entered into as of April 8, 2019 to the Master Collaboration Agreement dated as of January 11, 2014, as amended by Amendment No. 1 and Amendment No. 2, including...
(Filed With SEC on August 6, 2019)
-
Form of Ex-US Restricted/Performance Stock Unit Award Agreement under 2018 Stock Incentive Plan, as amended
(Filed With SEC on August 6, 2019)
-
2018 Stock Incentive Plan, as amended
(Filed With SEC on August 6, 2019)
-
Amended and Restated 2004 Employee Stock Purchase Plan, as amended
(Filed With SEC on May 2, 2019)
-
Underwriting Agreement, dated January 14, 2019, between Alnylam Pharmaceuticals, Inc. and Barclays Capital Inc
(Filed With SEC on January 15, 2019)